Paul Moore

Chief Scientific Officer Zymeworks

Dr Moore has 30 years of experience in biologics drug discovery supporting the development of a range of FDA-approved and clinical-stage biologics for both cancer and autoimmune patients. He presently serves as the Chief Scientific Officer at Zymeworks driving early stage RnD efforts focused on the discovery and development of next generation ADCs and multispecific antibody therapeutics, with multiple therapeutics in or on track to enter clinical development. Prior to Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he supported development of >15 antibody-based therapeutics from conception through IND to early-stage clinical testing (including multiple TCEs, Fc-modified antibodies, (dual) checkpoint inhibitors, and ADCs). He began his biotech career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development. There he led various genomic-based programs resulting in the discovery and biological characterization of multiple novel cytokines (inc. IFN-k and TNF like molecules TL1A and BLyS), novel signal transduction molecules (inc. IRF3) and a portfolio of protein therapeutics including long-acting cytokines and peptides (inc. GLP-1) that progressed to clinical development. Notably these efforts provided scientific rationale for the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received a PhD in molecular genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 80 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Seminars

Tuesday 9th March 2027
Enhancing the Therapeutic Potential of Topoisomerase Inhibitor ADCs: From Concept to Clinical Validation
2:45 pm
  • Learnings from 40+ years of ADC clinical development guiding ZD06519 Topo1i linker-payload design
  • Presenting Phase 1 clinical proof of concept studies with ZW191, supporting a potential best-in-class Folate receptor alpha targeting ADC
  • Applying ZD06519 to additional targets/ antibody formats to expand tumour type coverage and address target/tumour specific biology
Paul Moore - Zymeworks